Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:1199-1205

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caballero, R.
Right arrow Articles by Tamargo, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caballero, R.
Right arrow Articles by Tamargo, J.
Related Collections
Right arrow Ion channels/membrane transport

(Circulation. 2000;101:1199.)
© 2000 American Heart Association, Inc.


Basic Science Reports

Losartan and Its Metabolite E3174 Modify Cardiac Delayed Rectifier K+ Currents

Ricardo Caballero, BPharm; Eva Delpón, BPharm, PhD; Carmen Valenzuela, BSc, PhD; Mónica Longobardo, BPharm; Juan Tamargo, MD, PhD, FESC

From the Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain.

Correspondence to Eva Delpón, Department of Pharmacology, School of Medicine, Universidad Complutense, 28040 Madrid, Spain.

Background—The effects of type 1 angiotensin II receptor antagonist losartan and its metabolite E3174 on transmembrane action potentials, hKv1.5, HERG, and IKs currents were analyzed.

Methods and Results—Guinea pig ventricular action potentials were recorded with microelectrode techniques and hKv1.5 and HERG currents with the whole-cell patch-clamp technique. IKs was recorded in guinea pig ventricular myocytes with the perforated-nystatin-patch configuration. Losartan and E3174 transiently increased the hKv1.5 current by 8.0±1.4% and 7.4±1.6%, respectively. Thereafter, they produced a voltage-dependent block, E3174 being more potent than losartan (P<0.05) for this effect. Losartan decreased HERG currents elicited at 0 mV (23.3±4.8%), whereas E3174 increased the current (30.5±6.2%). Both drugs shifted the midpoint of the activation curve of HERG channels to more negative potentials. In ventricular myocytes, losartan and E3174 inhibited the IKs (18.4±3.2% and 6.5±0.7%, respectively). Losartan-induced block was voltage-independent, whereas E3174 shifted the midpoint of the activation curve to more negative potentials. Losartan lengthened the duration of the action potentials at both 50% and 90% of repolarization, whereas E3174 slowed only the final phase of the repolarization process.

Conclusions—These results demonstrated that at therapeutic concentrations, both losartan and E3174 modified the cardiac delayed rectifier hKv1.5, HERG, and Ks currents.


Key Words: losartan • E3174 • ion channels • myocytes • electrophysiology




This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
B. Ozben, M. Sumerkan, A. M. Tanrikulu, N. Papila-Topal, A. S. Fak, and A. Toprak
Perindopril decreases P wave dispersion in patients with stage 1 hypertension
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 85 - 90.
[Abstract] [PDF]


Home page
Mol. Biol. CellHome page
A. S. Tutor, E. Delpon, R. Caballero, R. Gomez, L. Nunez, M. Vaquero, J. Tamargo, F. Mayor Jr., and P. Penela
Association of 14-3-3 Proteins to beta1-Adrenergic Receptors Modulates Kv11.1 K+ Channel Activity in Recombinant Systems
Mol. Biol. Cell, November 1, 2006; 17(11): 4666 - 4674.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J., March 1, 2006; 27(5): 512 - 518.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Caballero, R. Gomez, L. Nunez, I. Moreno, J. Tamargo, and E. Delpon
Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations
Cardiovasc Res, December 1, 2004; 64(3): 457 - 466.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. F. Tomaselli and D. P. Zipes
What Causes Sudden Death in Heart Failure?
Circ. Res., October 15, 2004; 95(8): 754 - 763.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res, April 1, 2004; 62(1): 9 - 33.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Caballero, I. Moreno, T. Gonzalez, C. Arias, C. Valenzuela, E. Delpon, and J. Tamargo
Spironolactone and Its Main Metabolite, Canrenoic Acid, Block Human Ether-a-Go-Go-Related Gene Channels
Circulation, February 18, 2003; 107(6): 889 - 895.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
I. Moreno, R. Caballero, T. Gonzalez, C. Arias, C. Valenzuela, I. Iriepa, E. Galvez, J. Tamargo, and E. Delpon
Effects of Irbesartan on Cloned Potassium Channels Involved in Human Cardiac Repolarization
J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 862 - 873.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Caballero, I. Moreno, T. Gonzalez, C. Valenzuela, J. Tamargo, and E. Delpon
Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5)
Cardiovasc Res, October 1, 2002; 56(1): 104 - 117.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Caballero, E. Delpón, C. Valenzuela, M. Longobardo, T. González, and J. Tamargo
Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization
Mol. Pharmacol., April 1, 2001; 59(4): 825 - 836.
[Abstract] [Full Text]